{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01456819",
      "OrgStudyIdInfo": {
        "OrgStudyId": "FF-113-2011"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "NMRR-11-904-9763",
            "SecondaryIdType": "Registry Identifier",
            "SecondaryIdDomain": "National Medical Research Register"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "National University of Malaysia",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia",
      "OfficialTitle": "Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2015",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 2016",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 4, 2011",
      "StudyFirstSubmitQCDate": "October 19, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 21, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "April 9, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 10, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Dr Hanafiah Harunarashid",
        "ResponsiblePartyInvestigatorTitle": "Senior Consultant Vascular Surgeon",
        "ResponsiblePartyInvestigatorAffiliation": "National University of Malaysia"
      },
      "LeadSponsor": {
        "LeadSponsorName": "National University of Malaysia",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Cytopeutics Sdn. Bhd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a randomized and single blinded study aimed to compare the efficacy between intramuscular autologous bone marrow mononuclear cells plus mesenchymal stem cell implantation and intramuscular autologous bone marrow mononuclear cells implantation only in patients with chronic critical limb ischemia. Patients will be randomized into two groups of equal number; patients in one group will be implanted with mononuclear cells and mesenchymal stem cells, and the other implanted with mononuclear cells only in the area of affected limb.",
      "DetailedDescription": "When the long blood vessels supplying blood to the arms and legs become blocked (ischemic), patient will experience painful sensations in their calves when they walked which slowly become excruciating painful at rest. When the condition worsens, the patients will not be able to feel any pain from their legs and they will not know if there are any small ulcers or cuts on their legs. As a result, a small ulcer which goes unnoticed becomes bigger and can sometimes become infected. In the worst situations, infection might lead towards gangrene and septicaemia. Severe rest pain and/or ulcerations of ischemic limbs are defined as the state of chronic critical limb ischemia and at this point, amputation of the affected limb is suggested.\n\nConventional treatments include angioplasty/bypass operation to remove blood vessel blockage to restore blood supply, the use of prescribed medicines to aid in ulcer recovery and clear infection and debridement of damaged/infected tissue. Some procedures have to be performed multiple times. Amputation is inevitable in many cases because some blood capillaries cannot be corrected and restenosis of vessels is very common. Cell therapy with mononuclear cells and mesenchymal stem cells from bone marrow is promising because these stem cells are capable of stimulating and regenerating capillaries and blood vessels."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Critical Limb Ischemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "autologous",
          "bone marrow",
          "critical limb ischemia",
          "efficacy",
          "mesenchymal stem cells",
          "mononuclear cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "50",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mononuclear and mesenchymal stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mononuclear and mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Mononuclear cells only",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Autologous bone marrow-derived mononuclear cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mononuclear cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mononuclear and mesenchymal stem cells",
            "InterventionDescription": "Intramuscular administration into the ischemic limb",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mononuclear and mesenchymal stem cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "BM-MNC and BM-MSC"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Mononuclear cells",
            "InterventionDescription": "Intramuscular administration into the ischemic limb",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mononuclear cells only"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "BM-MNC"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in angiogenesis",
            "PrimaryOutcomeDescription": "Measurement of angiogenesis by presence of peripheral pulses, capillary refill and transcutaneous oxygen saturation (TCOS).",
            "PrimaryOutcomeTimeFrame": "1 month, 3 months, 6 months, 9 months, 12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in ulcer size",
            "SecondaryOutcomeDescription": "Measurement of ulcer size by clinical assessment and grid maps.",
            "SecondaryOutcomeTimeFrame": "1 month, 3 months, 6 months, 9 months, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Visual Analog Score",
            "SecondaryOutcomeTimeFrame": "1 month, 3 months, 6 months, 9 months, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Exercise Treadmill Test",
            "SecondaryOutcomeTimeFrame": "1 month, 3 months, 6 months, 9 months, 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement in vascularity and blood supply",
            "SecondaryOutcomeDescription": "Measured by digital subtraction angiography (DSA) and ankle brachial systemic pressure index (ABI).",
            "SecondaryOutcomeTimeFrame": "1 month, 3 months, 6 months, 9 months and 12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nClinical diagnosis of critical limb ischemia leading to ischemic ulcers in which amputation is indicated\nNot suitable for, or remain symptomatic despite angioplasty, bypass operation or collateralization\n\nExclusion Criteria:\n\nContraindication to epidural anesthesia and bone marrow aspiration\nContraindication to contrast angiography\nEvidence of neoplasia and bone marrow diseases\nAny acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV\nPatients with a limited life expectancy (< 1 year)\nPatients with myocardial infarction or stroke within 6 months\nPatients with coronary intervention within 6 months\nRenal impairment indicated by serum creatinine greater than two times upper limit of the normal range\nLiver impairment indicated by serum aspartate transaminase and alanine transaminase greater than two times upper limit of normal\nAny other co-morbidity which the physician deems as a contraindication to stem cell transplantation",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Hanafiah Harunarashid, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+60391456208",
            "CentralContactEMail": "hanafiah@ppukm.ukm.my"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Hanafiah Harunarashid, MD",
            "OverallOfficialAffiliation": "UKM Medical Centre",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "UKM Medical Centre",
            "LocationStatus": "Recruiting",
            "LocationCity": "Kuala Lumpur",
            "LocationZip": "56000",
            "LocationCountry": "Malaysia",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Hanafiah Harunarashid, MD",
                  "LocationContactRole": "Contact"
                },
                {
                  "LocationContactName": "Hanafiah Harunarashid, MD",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Mohammad Azim Mohammad Idris, MD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}